Skip to content
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Heart icon (animated) heart icon (static)
Our Stories
Our Company
Follow Us
Explore more Johnson & Johnson sites:
Australia
A graphic of the flag of Australia alt
Argentina
A graphic of the flag of Argentina alt
Brazil
A graphic of the flag of Brazil alt
Canada
A graphic of the national flag of Canada alt
Chile
A graphic of the flag of Chile alt
China
A graphic of the national flag of the People's Republic of China alt
Colombia
A graphic of the national flag of Colombia alt
Costa Rica
A graphic of the national flag of Costa Rica alt
Czech Republic
Ecuador
A graphic of the national flag of Ecuador alt
Germany
A graphic of the flag of Germany alt
India
A graphic of the national flag of India alt
Japan
A graphic of the national flag of Japan alt
Mexico
A graphic of the flag of Mexico alt
New Zealand / Pacific
A graphic of the flag of New Zealand alt
Paraguay
A graphic of the flag of Paraguay alt
Peru
A graphic of the flag of Peru alt
Philippines
A graphic of the national flag of the Philippines alt
Russia
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
German
English
French
United Kingdom
A graphic of the national flag of the U.K. alt
United States
A graphic of the flag of the United States of America alt
Uruguay
A graphic of the national flag of Uruguay alt
Venezuela
A graphic of the flag of Venezuela alt
Share

Pharmaceutical Pipeline

Download Report

Selected Pharmaceuticals in Late Stage U.S. and E.U. Development or Registration as of July 21, 2021

Therapeutic Area
Select All Reset
Changes
Cardiovascular and Metabolism Immunology Neuroscience
15 of 53 Total Indications

Cardiovascular and Metabolism

aprocitentan

Difficult to treat hypertension 2
Phase III US
Phase III EU

XARELTO (rivaroxaban)

Infrainguinal revascularized PAD 3
Filed 10/20 US

XARELTO (rivaroxaban)

Pediatric VTE/CHD (Fontan) 3
Filed 6/21 US

XARELTO (rivaroxaban)

COVID-19 MI (PREVENT-HD) 3
Phase III US

Immunology

nipocalimab​

Warm Autoimmune Hemolytic Anemia
Phase III US
Phase III EU

SIMPONI (golimumab)

Pediatric Ulcerative Colitis
Phase III US
Phase III EU

STELARA (ustekinumab)

Pediatric Crohn's Disease
Phase III US
Phase III EU

STELARA (ustekinumab)

Pediatric Ulcerative Colitis
Phase III US
Phase III EU

TREMFYA (guselkumab)

Crohn's Disease
Phase IIB/III US
Phase IIB/III EU

TREMFYA (guselkumab)

Pediatric Psoriasis
Phase III US
Phase III EU

TREMFYA (guselkumab)

Ulcerative Colitis Monotherapy
Phase IIB/III US
Phase IIB/III EU

TREMFYA (guselkumab)

Psoriatic Arthritis Structural Damage
Phase III US

Neuroscience

INVEGA HAFYERA (PP6M)

Treatment of Schizophrenia
Filed 10/20 US
Filed 11/20 EU

PONVORY (ponesimod)

Relapsing forms of Multiple Sclerosis
Approved 3/21 US
Approved 5/21 EU

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms
Phase III US
Phase III EU
This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. (2) aprocitentan developed in collaboration with Idorsia; (3) XARELTO co-developed with Bayer HealthCare; (5) DARZALEX licensed from Genmab A/S; (6) IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; (7) BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; (8) Niraparib licensed from Tesaro; (9) BCMA CAR-T licensed from Legend Biotech; (10) Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; (11) DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab);
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue